fashion -WSS

fashion

author：comprehensive 2025-08-04 12:32:02 - browse：18

Adam's take main illustration — Molly Ferguson/STAT

Anavex Life Sciences is in a tough spot. The serial dissembler of clinical trial results might be forced, finally, to tell the truth when it reads out its next study in Rett syndrome.

What sets Anavex apart from all the other biotechs on my radar screen is its habit of shifting the goalposts on clinical trials. Twice last year, first in February and then in December, Anavex announced “positive” outcomes from studies of its drug called blarcamesine — except the results were derived from efficacy endpoints that were not part of the original study designs.

If blarcamesine fails to achieve the pre-determined goals of clinical trials, the thinking apparently goes, then just make a post-hoc change to the study goals.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Virginia high school admissions case could be legal follow
Next article： In science, is the line between industry and academia shifting?

WSS

Readout LOUD podcast: mifepristone case, GLP

Patient advocates debate FDA's accelerated approval process

Patient advocates debate FDA's accelerated approval process

Readout Newsletter: Blackstone Life Sciences, Merck, Bluebird Bio

Neuroscience startup Neumora files for IPO

How to make AI work for medicine

focus

fashion

hotspot

Virginia high school admissions case could be legal follow

Covid vaccine financial winners and losers, from Pfizer to Novavax

Novavax promises a turnaround & Lilly roils the obesity market

What do new weight loss drugs mean for bariatric surgery?

After affirmative action ruling, medical educators look to 'holistic review'

How Long Island became the ‘eugenics capital of the world’

Heart attack and stroke risk calculators need revising

Decaf coffee targeted by food safety group under obscure FDA rule

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Neuroscience startup Neumora files for IPO

hotspot

Why the world’s most expensive drug might be worth the price

What AAP's gender

Roche subsidiary Foundation Medicine opens new headquarters

As pharma fights Medicare drug negotiation, hospitals, docs silent

How to make Best Hospitals ratings actually useful for patients

How a symptom of dementia informs our understanding of creativity

explore

leisure time

focus

hotspot